NCT00145470View on ClinicalTrials.gov

12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)

PHASE3CompletedINTERVENTIONAL

Enrollment

326

Participants

Timeline

Start Date

June 2, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

March 22, 2007

Conditions

Bipolar Disorder

Interventions

DRUG

Asenapine

Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.

DRUG

Placebo

Placebo fast dissolving SL tablets, BID

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00145470 - 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017) | Biotech Hunter | Biotech Hunter